Do fibromyalgia patients substitute CBD products for pain medications ?
Yes. According to a cross-sectional survey of fibromyalgia patients (n= 878 individuals), “the majority (n = 632, 72.0%) reported substituting CBD products for medications, most commonly NSAIDs (59.0%), opioids (53.3%), gabapentanoids (35.0%), and benzodiazepines (23.1%)…The most common reasons for substitution were fewer side effects and better symptom management.” Seventy to 94% of reported substitutions resulted in stopped or reduced use of medications.
In 2020, how many people aged 12 or older misused opioids within the preceding year?
Among people aged 12 or older in 2020, 3.4% (or 9.5 million people) misused opioids in
the past year. Among the 9.5 million people who misused opioids in the past year, 9.3
million people misused prescription pain relievers and 902,000 people used heroin.
” Inadequate Medical Information Available Regarding Cannabis Use in MS
A survey on cannabis use of participants in the “North American Research Committee on Multiple Sclerosis (NARCOMS)” questioned patients about the source of their cannabis medical guidance. Did most cannabis users obtain their medical guidance from their physicians?
No. “Among those who reported ever using cannabis (n = 1012), 70% of patients discussed it with a physician treating MS, BUT only 12% obtained medical guidance. In total, 48% of ever users reported that either nobody or themselves was the primary person providing medical guidance for cannabis use. Dispensary professionals, used by 21% of the entire cohort, were the second most, ahead of MS physician (12%), other physicians (8%), other patients with MS (8%), other licensed healthcare providers (3%), and pharmacists (1%).”
According to a study published in the October 2021 edition of Cancer, what is the most common time for breast cancer patients to use cannabinoid-based products: pre-treatment, during treatment or after treatment?
24% used the cannabinoids pre-treatment, 79% during treatment and 54% after treatment. According to the authors of the study, there is limited data on potential drug interactions between cannabinoids and the prescribed cancer treatment medications.
Do some cancer patients who use cannabis-based products believe that cannabinoids can cure cancer?
Yes. Some patients believe that cannabinoids can cure cancer. (IMPORTANT: To date, it has not been shown that cannabinoids cure cancer in humans.) According to a study published in Cancer, 49% of the surveyed breast cancer patients who use cannabis believed that medical cannabis could be used to treat cancer itself.
According to a study published in the October 2021 edition of Cancer, what are the most common reasons for breast cancer patients to use cannabinoid-based products?
Patients most often used cannabinoid-based products for pain (78%), anxiety (57%), stress (51%) and nausea (46%). 75% of these patients considered the cannabinoids to be extremely or very helpful for relieving their symptoms and 57% of users had found no alternative for treating their symptoms.
What are the most common target symptoms for which multiple sclerosis (MS) patients use cannabinoid-based products?
According to a survey of 1,012 MS patients conducted through the “North American Research Committee on Multiple Sclerosis (NARCOMS) Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis,” the most common target symptoms for which patients used cannabis were: spasticity (80%), pain (69%), and sleep (61%). The most preferred composition of cannabis-based products were: 50:50 THC:CBD (31%) and high THC/low CBD (30%).
In 2020, how many people in the US used marijuana for recreational purposes?
According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) 2020 National Survey of Drug Use and Health, 49.6 million people used marijuana. When stratified for age, the percentage of people who used marijuana in the past year was highest among young adults ages 18 to 25 (34.5%) followed by those ages 26 or older (16.3% ) and adolescents ages 12 to 17 (10.1%).
Are food and beverages containing CBD allowed to be sold in stores (other than dispensaries) and restaurants?
According to the Food and Drug Administration (FDA), no. But California Governor Gavin Newsom signed into law Assembly Bill 45 (AB-45) that “prohibit[s] restrictions on the sale of dietary supplements, food, beverages, cosmetics, or pet food that include industrial hemp or cannabinoids, extracts, or derivatives from industrial hemp based solely on the inclusion of those substances.” AB-45 departs from the FDA’s guidance that CBD cannot be introduced to food products or dietary supplements sold in interstate commerce.
Is there any evidence of the therapeutic value of medical marijuana for multiple myeloma (MM) patients?
Two recent PRECLINICAL studies indicate that cannabinoids (CBD and THC) may enhance the efficacy of some chemotherapeutic agents. The results of a study by Morelli et al. found that “the combination of cannabidiol and proteosome inhibitor bortezomib was more effective in inducing MM cell death than bortezomib alone.” Also, a study by Nabissi et al. “found a synergistic effect between Δ -tetrahydrocannabinol, cannabidiol, and cytotoxic agent carfilzomib, resulting in strong anti-cancer activity; it reduced MM cell viability by inducing autophagic-cell death and inhibited MM cell migration by down-regulating expression of chemokine receptor CXCR4 and the CD147 plasma membrane glycoprotein.”
Shapiro, Y.N., Peppercorn, J.M., Yee, A.J. et al. Lifestyle considerations in multiple myeloma. Blood Cancer J. 11, 172 (2021). https://doi.org/10.1038/s41408-021-00560-x Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, et al. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer. 2014;134:2534–46. https://doi.org/10.1002/ijc.28591. Nabissi M, Morelli MB, Offidani M, Amantini C, Gentili S, Soriani A, et al. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016;7:77543–57. https://doi.org/10.18632/oncotarget.12721